Focused On-demand Library for Conserved oligomeric Golgi complex subunit 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8WTW3

UPID:

COG1_HUMAN

Alternative names:

Component of oligomeric Golgi complex 1

Alternative UPACC:

Q8WTW3; Q9NPV9; Q9P2G6

Background:

The Conserved oligomeric Golgi complex subunit 1, also known as Component of oligomeric Golgi complex 1, plays a pivotal role in maintaining normal Golgi function. This protein is essential for the proper processing and sorting of proteins, ensuring they are correctly glycosylated and directed to their destination within the cell. Glycosylation, a critical post-translational modification, is crucial for protein stability, signaling, and cell-cell interactions.

Therapeutic significance:

Given its involvement in Congenital disorder of glycosylation 2G (CDG2G), a multisystem disorder characterized by defects in glycoprotein biosynthesis leading to a wide array of clinical features, understanding the role of Conserved oligomeric Golgi complex subunit 1 could open doors to potential therapeutic strategies. Targeting the underlying glycosylation defects presents a promising avenue for treating CDG2G and improving patient outcomes.